Evidence map›Paper›PMID 29753157›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

Eneida R Nemecek, Ralf A Hilger, Alexia Adams, Bronwen E Shaw, Deidre Kiefer, Jennifer Le-Rademacher, John E Levine, Gregory Yanik, Wing Leung, Julie-An Talano and 15 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 1 country.

Eneida R NemecekDoernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon. Electronic address: nemeceke@ohsu.edu.
Ralf A HilgerWest German Cancer Center, University Hospital Essen, University Duisburg Essen, Essen, Germany.
Alexia AdamsCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Deidre KieferCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Jennifer Le-RademacherDivision of Pediatric Hematology/Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
John E LevineDivision of Pediatric Hematology/Oncology, Mount Sinai School of Medicine, New York, New York.
Gregory YanikDivision of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Wing LeungDivision of Pediatric Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Julie-An TalanoDivision of Pediatric Hematology/Oncology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin.
Paul HautDivision of Pediatric Hematology/Oncology, Riley Children's Hospital at Indiana University Health, Indianapolis, Indiana.
David DelgadoDivision of Pediatric Hematology/Oncology, Riley Children's Hospital at Indiana University Health, Indianapolis, Indiana.
Neena KapoorChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine at University of Southern California, Los Angeles, California.
Aleksandra PetrovicDivision of Pediatric Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Roberta AdamsDivision of Pediatric Hematology/Oncology, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, Arizona.
Rabi HannaDivision of Pediatric Hematology/Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
Hemalatha RangarajanDivision of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, Ohio.
Jignesh DalalDivision of Pediatric Hematology/Oncology, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
Joseph ChewningChildren's of Alabama, University of Alabama at Birmingham, Birmingham, Alabama.
Michael R VernerisDivision of Pediatric Hematology/Oncology, University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota.
Stacy EpsteinLevine Children's Hospital, Carolinas Medical Center, Charlotte, North Carolina.
Lauri BurroughsFred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
Evelio D Perez-AlbuerneChildren's National Health System, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
Michael A PulsipherChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine at University of Southern California, Los Angeles, California.
Colleen DelaneyFred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
Indiana University Health · USNational Marrow Donor Program · USUniversity of Southern California · USUniversity of Washington · USCarolinas Medical Center · USChildren's Hospital of Wisconsin · USChildren's Mercy Hospital · USChildren's National · USChildren's of Alabama · USCleveland Clinic · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USMayo Clinic · USMedical College of Wisconsin · USNationwide Children's Hospital · USOregon Health & Science University · USPhoenix Children's Hospital · USSt. Jude Children's Research Hospital · USUniversity of Michigan · USUniversity of Minnesota Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (range, 1 to 19) underwent allogeneic HCT for AML in first (n = 18), second (n = 11), and third or greater remission (n = 3) or MDS (n = 8) using bone marrow (n = 25), peripheral blood stem cells (n = 5), or cord blood (n = 9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m

Indexed as

Whole-Body IrradiationAdolescentBusulfanChildChild, PreschoolFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInfantLeukemia, Myeloid, AcuteMaleMyelodysplastic SyndromesSurvival AnalysisTransplantation, HomologousBusulfanfludarabinetreosulfanVidarabineAcute myeloid leukemiaConditioning regimenMyelodysplastic syndromesStem cell transplantation

Identifiers

PMID29753157
PMCPMC6108922
OpenAlexW2802896371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.